The effect of rifaximin on gut flora and Staphylococcus resistance. (Q54263702)

27 May 2018

title

The effect of rifaximin on gut flora and Staphylococcus resistance. (English)

1 reference

27 May 2018

main subject

rifaximin

1 reference

ChEBI release 2020-05-28

8

Mark Pimentel

1 reference

27 May 2018

Mi-Sung Kim

1

1 reference

27 May 2018

Walter Morales

2

1 reference

27 May 2018

Andres Ardila Hani

3

1 reference

27 May 2018

Sharon Kim

4

1 reference

27 May 2018

Gene Kim

5

1 reference

27 May 2018

Stacy Weitsman

6

1 reference

27 May 2018

Christopher Chang

7

1 reference

27 May 2018

publication date

16 April 2013

1 reference

27 May 2018

Digestive Diseases and Sciences

published in

1 reference

27 May 2018

volume

58

1 reference

27 May 2018

issue

6

1 reference

27 May 2018

page(s)

1676-1682

1 reference

27 May 2018

Rifaximin: in vitro and in vivo antibacterial activity--a review

cites work

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

A new rat model links two contemporary theories in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Optimization of Real-Time PCR Assay for Rapid and Sensitive Detection of Eubacterial 16S Ribosomal DNA in Platelet Concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Management of colonic diverticular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Rifaximin in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Microbial flora in NSAID-induced intestinal damage: a role for antibiotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-013-2675-0

Rifaximin systemic absorption in patients with ulcerative colitis

21 January 2018

1 reference

12 December 2020

Rifaximin intake leads to emergence of rifampin-resistant staphylococci

1 reference

12 December 2020

Interruption of Recurrent Clostridium difficile-Associated Diarrhea Episodes by Serial Therapy with Vancomycin and Rifaximin

1 reference

12 December 2020

Sensitivity to rifaximin and rifampicin of Mycobacterium tuberculosis isolated from guinea pigs treated orally with rifaximin.

1 reference

12 December 2020

Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin

1 reference

12 December 2020

Characterization of mutations in the rpoB gene that confer rifampin resistance in Staphylococcus aureus

1 reference

12 December 2020

Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis

1 reference

12 December 2020

Pharmacokinetic study of rifaximin after oral administration in healthy volunteers.

1 reference

12 December 2020

Review of rifaximin as treatment for SIBO and IBS

1 reference

12 December 2020

The specific inhibition of the DNA-directed RNA synthesis by rifamycin

1 reference

12 December 2020

Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin

1 reference

12 December 2020

10.1007/S10620-013-2675-0

Identifiers

DOI

1 reference

27 May 2018

1 reference

27 May 2018